Streetbeat News

Stock Prices

AVXL

Anavex Life Sciences Corp announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate a disease-modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome. The data shows that blarcamesine exhibited both symptomatic and disease-modifying effects for Rett syndrome in a clinical setting. Despite the positive news, AVXL shares are down 1.67% at $7.95 on the last check Wednesday.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 6:02 pm

CNTG

CENTOGENE (CNTG) shares are trading higher following the announcement of a joint venture with Lifera in Saudi Arabia. The deal includes a $30 million mandatory convertible loan from Lifera to CENTOGENE.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 6:01 pm

WMS

Over the past 3 months, 10 analysts have published their opinion on Advanced Drainage Systems (NYSE:WMS) stock. The company has an average price target of $114.6, up by 3.45% from the previous average price target of $110.78. The analysts' ratings range from bullish to indifferent, with no bearish ratings.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:01 pm

VALE

In the last quarter, Vale (NYSE:VALE) received three somewhat bullish ratings and one indifferent rating from analysts. The average 12-month price target for the company is $16.5, representing a 5.71% decrease from the previous average price target of $17.50.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:01 pm

PGR

Progressive (NYSE:PGR) has outperformed the market over the past 20 years by 2.63% on an annualized basis, producing an average annual return of 10.22%. If an investor had bought $100 of PGR stock 20 years ago, it would be worth $700.76 today.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:01 pm

ORCL

Oracle (NYSE:ORCL) has outperformed the market over the past 20 years by 4.23% on an annualized basis, producing an average annual return of 11.82%. If an investor had bought $1000 of ORCL stock 20 years ago, it would be worth $9,345.66 today.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:00 pm

WIX

In the last quarter, Wix.com (NASDAQ:WIX) received 3 bullish, 6 somewhat bullish, and 1 indifferent analyst ratings. Over the past 3 months, 10 analysts have offered 12-month price targets for Wix.com, with an average price target of $111.1. This average price target has increased by 6.83% over the past month.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:00 pm

TW

Over the past 3 months, 10 analysts have published their opinion on Tradeweb Markets (NASDAQ:TW) stock. The company has an average price target of $84.8, an increase of 6.19% from the previous average price target of $79.86. The majority of the analysts are bullish on the stock.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:00 pm

BMY

SLS

SELLAS Life Sciences Group Inc (SLS) released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co's (BMY) nivolumab in patients with malignant pleural mesothelioma. The results showed improved survival rates with no dose-limiting toxicities observed. However, SLS shares are down 1.22%.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 6:00 pm

LYFT

Over the last quarter, Lyft (NASDAQ:LYFT) has received 4 somewhat bullish and 7 indifferent analyst ratings. The average 12-month price target for the company is $12.59, a decrease of 50.47% from the previous average of $25.42. No bullish or bearish ratings were observed.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 6:00 pm